Abstracts - PAGE Meeting (Population Approach Group Europe)

← Back to filters

Abstracts (29)

B-03Amin Rostami

OrBiTo – translating mechanistic knowledge on absorption into predictive models

Wednesday 09:00-09:40

B-04Benjamin Guiastrennec

Mechanism-based modelling of gastric emptying and bile release in response to caloric intake

Wednesday 09:40-10:00

B-05Andrés Olivares-Morales

An in silico physiologically-based pharmacokinetic (PBPK) study of the impact of the drug release rate on oral absorption, gut wall metabolism and relative bioavailability

Wednesday 10:00-10:20

B-07Kapil Gadkar

Development of Virtual Population for a Quantitative Systems Pharmacology model

Wednesday 11:50-12:10

B-08Maciej Swat

PharmML 1.0 – An Exchange Standard for Models in Pharmacometrics

Wednesday 12:10-12:30

B-09Marc Gastonguay

Proposal for a Web-Based Open Pharmacometrics Curriculum

Wednesday 12:30-12:40

B-11Pierre Marquet

Model-based personalized medicine in transplantation

Wednesday 14:10-14:50

B-12Núria Buil Bruna

A step forward toward personalised medicine in oncology: Population modelling for the early prediction of disease progression using biomarkers

Wednesday 14:50-15:10

B-14Julia Korell

Application of a model based longitudinal network meta-analysis of FEV1 in COPD trials in clinical drug development

Wednesday 16:30-16:50

B-15Sebastian Weber

Bayesian Drug Disease Model with Stan – Using published longitudinal data summaries in population models

Wednesday 16:50-17:10

B-16Angelica Quartino

An integrated natural disease progression model of nine cognitive and biomarker endpoints in patients with Alzheimer’s Disease

Wednesday 17:10-17:30

B-17Yaming Hang

Pharmacokinetic and Pharmacodynamic Analysis of Longitudinal Gd-Enhanced Lesion Count in Subjects with Relapsing Remitting Multiple Sclerosis Treated with Peginterferon beta-1a

Wednesday 17:30-17:50

C-01Tram Nguyen

Handling data below the quantification limit in viral kinetic modeling for model evaluation and prediction of treatment outcome

Thursday 08:45-09:10

C-02

Development of population based approaches to describe the complex pharmacokinetics of simvastatin in different individuals. Bridging the gap between population and physiologically based pharmacokinetic modelling.

Thursday 09:10-09:35

C-03Mélanie Wilbaux

A dynamic K-PD joint model for the kinetics of CTC (Circulating Tumor Cell) count and PSA concentration during treatment in metastatic castration-resistant prostate cancer

Thursday 09:35-10:00

C-06Scott Marshall

Good Practices in Model Informed Drug Discovery and Development (MID3): Practice, Application, Documentation and Reporting

Thursday 11:30-11:50

C-07

How European Regulators are Facilitating the Use of Modelling and Simulation: MSWG History, Activity and Future

Thursday 11:50-12:15

C-08Efthymios Manolis

EMA qualification of novel methodologies: are we ready for M&S ?

Thursday 12:15-12:35

C-11Björn Bornkamp

The MCP-Mod methodology – A statistical methodology for dose-response

Thursday 14:15-14:40

C-12

The Role of Model Based Drug Development – Is it time to repaint the canvas?

Thursday 14:40-15:15

C-14Camille Vong

In silico comparison of MTD determination in a phase I dose-finding framework

Thursday 16:40-17:00

C-15Coen van Hasselt

Towards early integrated mechanism-based prediction of clinical outcome and cost-effectiveness in castration-resistant prostate cancer

Thursday 17:00-17:20

D-01Edouard Ollier

Group comparison with fused lasso penalized likelihood: an alternative to test based methods

Friday 09:00-09:20

D-02Elin Svensson

Prediction of pharmacokinetic interactions for drugs with a long half-life – evidence for the need of model-based analysis

Friday 09:40-09:40

D-03Yasunori Aoki

Averaged Model Based Decision Making for Dose Selection Studies

Friday 09:40-10:00

D-06Sharon Hori

Modeling cancer blood biomarker dynamics in relation to tumor growth

Friday 10:50-11:10

D-07Rik de Greef

Modeling of tumor size reduction patterns in advanced melanoma under treatment with MK-3475, a potent antibody against PD-1

Friday 11:10-11:30

D-08

A mixed-effect modeling framework to personalize treatment of low-grade glioma patients

Friday 11:30-11:50

D-09Nick Holford

Power and Type 1 Error of Tumour Size Metrics Used to Predict Survival

Friday 11:50-12:10